Company Overview
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. Its therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. The company has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -75.85% |
| 6 Months: | +18.06% |
| 3 Months: | -23.42% |
| 1 Month: | +14.09% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)56.09 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 89.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MTVA MetaVia Inc. PHARMA | 1.70 | -0.69 | $11.20M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | -1.59M | -1.61M | -2.37M | -2.51M | -2.23M | -1.84M | -3.40M | -7.23M | -7.50M | -10.52M | -8.54M | -6.57M | -7.06M | -6.53M | -5.91M | -3.30M | -2.45M | -1.89M | -3.65M | -4.75M | -2.39M | -3.06M | -3.33M | -3.93M | -3.46M | -2.88M | -3.22M | -3.10M | -2.52M | -3.81M | -3.89M | -6.88M | -10.08M | -6.26M | -3.89M | -4.30M | -3.48M | -4.03M | -5.38M |
| Net Income | -196.00K | -2.28M | -1.61M | -2.57M | -2.57M | -2.10M | -1.39M | -3.88M | -7.21M | -7.50M | -10.50M | -8.67M | -6.75M | -7.22M | -6.68M | -6.08M | -3.66M | -2.46M | -1.90M | -3.62M | -4.73M | -2.38M | -3.05M | -3.32M | -3.92M | -3.46M | -2.88M | -3.30M | -3.11M | -2.60M | -734.00K | -3.82M | -6.71M | -10.05M | -5.65M | -3.67M | -4.00M | -3.38M | -3.82M | -5.32M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.19 | -0.15 | -0.18 | -4.66 | -3.24 | -3.72 | -3.50 | -0.51 | -0.15 | -0.75 | -1.32 | -1.85 | -0.55 | -3.93 | -0.26 | -0.14 | -0.79 | -0.90 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 186.00K | - | - | - | - | - | - | - | - | - | - | - | - | 8.07M | 4.52M | 2.33M | 2.32M | 1.91M | 2.10M | 3.48M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Oct 2014 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | -266.00K | -8.08M | -14.70M | -33.12M | -15.49M | -20.18M | -29.72M | -15.30M | -19.63M | -15.89M | -28.81M | -13.71M |
| Net Income | -124.00K | -320.00K | -9.03M | -14.59M | -33.41M | -15.53M | -21.31M | -29.68M | -15.28M | -13.97M | -12.47M | -27.59M | -12.97M |
| Diluted EPS | - | - | - | - | - | - | - | -1.83 | -19.81 | -43.42 | -2.46 | -39.13 | -7.35 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | - | 21.55M | 6.80M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 4.49M | 24.75M | 19.02M | 3.82M | 14.47M | 10.97M | - | 33.53M | 22.78M | 16.26M | 11.12M |
| Current Assets | - | - | - | - | - | - | - | - | - | 33.53M | 22.51M | 16.07M | 10.88M |
| Cash & Equivalents | 3.00K | 317.00K | 3.62M | 24.03M | 18.47M | 2.85M | 13.91M | 10.09M | - | 33.36M | 22.43M | 16.02M | 10.28M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | 8.92M | 4.12M | 15.08M | 360.00K | 2.18M | 3.77M | - | 11.78M | 6.10M | 8.33M | 5.79M |
| Current Liabilities | - | - | 8.92M | 4.12M | 6.39M | 219.00K | 2.08M | 3.69M | - | 11.78M | 5.96M | 8.27M | 5.65M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | 0 | 203.00K | 136.00K | 210.00K |
| Total Equity | -264.00K | -531.00K | -12.38M | 20.63M | 25.00K | -13.29M | 12.29M | 7.20M | - | 21.75M | 16.68M | 7.93M | 5.33M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | 289.05K | 446.00K | 785.19K | 2.31M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -5.43M | -11.04M | -26.90M | -14.45M | -7.04M | -10.76M | -15.13M | -11.71M | -10.80M | -24.71M | -15.70M |
| Investing Cash Flow | - | - | - | -3.00K | -6.06M | 69.00K | -586.00K | 8.00K | -50.00K | -8.00K | -2.00K |
| Financing Cash Flow | 8.74M | 31.46M | 21.34M | 17.25M | 24.17M | 6.86M | 22.03M | 28.68M | -80.00K | 18.30M | 9.96M |
| Capital Expenditure | - | - | - | -3.00K | -214.00K | -4.00K | -3.00K | - | -50.00K | -8.00K | -2.00K |
| Free Cash Flow | - | - | - | -14.45M | -7.25M | -10.77M | -15.14M | - | -10.85M | -24.72M | -15.70M |
Ratios (Annual)
Figures in %.
| Metric | Oct 2014 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | - | 60.3% | 72.9% | -70.7% | -133,660.0% | 116.9% | -173.4% | -412.0% | - | -64.2% | -74.7% | -347.9% | -243.3% |
| ROCE % | - | - | 182.4% | -71.2% | -262.3% | -430.0% | -162.9% | -408.6% | - | -90.2% | -94.4% | -360.6% | -250.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC | 2.39% | 123.58K | $213.80K |
| 2 | Citadel Advisors Llc | 1.19% | 61.21K | $105.89K |
| 3 | Virtu Financial LLC | 0.58% | 29.93K | $51.78K |
| 4 | Geode Capital Management, LLC | 0.41% | 21.31K | $36.87K |
| 5 | UBS Group AG | 0.25% | 12.95K | $22.40K |
| 6 | Scientech Research LLC | 0.23% | 12.01K | $20.78K |
| 7 | Aries Wealth Management | 0.19% | 10.00K | $17.30K |
| 8 | Vanguard Capital Management LLC | 0.17% | 8.92K | $15.43K |
| 9 | Vanguard Fiduciary Trust Co | 0.13% | 6.94K | $12.01K |
| 10 | Tower Research Capital LLC (TRC) | 0.04% | 2.22K | $3.85K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MTVA
MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update - PR Newswire
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxQR0VLOWEzdEdFV2hGRE9vMmo2ckowU1hjRm54LU1rVVZ4a1lWQS13YzZvdDlXbllmekhlNHpETVZBWEY4b1F2dkJ2dm8xamt6dElkVVhlLWFNakI1U3JEZUVOQjY0YVBUbDJRbnZDR0VZQjllZEYzRGhyLWowOEFud2FRUWg3NkRRQWY0MT…
MTVA Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBpcGJWeThuSEdCQ1QyQkl0aVZTOWM1eF9ldnh4dS1tQXVrd1doenhlRHREbVhpb1ZlSkkxTTdSd1A2aVhSWmZxc3VUTi1ULW4xTTlJaTdsS3hia3lfSjRsUjg0Rlg5MGRSS2x6VUdtUi04WXNYTzk5VW5B?oc=5" target="_blank">MTV…
MTVA Stock (MTVA) Opinions on Recent Trading Breakouts - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxQUkRpNVBMdWpZWWtMVnBmUFdTbDczZl9tSmFiUGk4UVd1cGU3dFJkdXp3OFhMRVJ4d1ZwcVlDYjlVc1V0WEpZeDlBZWh2VEdmUW4zNjZkMzdVbXZSSDZDa2V0akhKVXZLd1FwY3oxalhrbEhIOVJsSjMtNGkxSGZhMmRlbHRuWHZDSVVYLW…
Why MetaVia Stock Is Falling On Thursday? - MetaVia (NASDAQ:MTVA) - Benzinga
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNQ3U3YXJ6QjhLSUNmVDZROWVhLXlqR2RnV3N0VDJBbmJEbDZrN0ZJRVZGOEVSdVlkOTlfSTRmSUZSUjNLQUFWRXlLT3JCaWhfbG1UcDFnS0U2REZiclFUVTdRVTB3bHdJSENPdDIxZmJ0eXNFUXV0LUF6MXQ2S3hKVmFlbVA2UGxEalNvaU…
MTVA Stock Sees Volatile Spike As Traders Eye Cash-Heavy Balance Sheet - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMickFVX3lxTE5acFE3LU9rOW1hZ1dYQnRpTGZaOGd5MnlCQWdSOWtRZEFhczc1bTFVS01BRGpUbEN5eUpXbHpZVHpZUFpxZWNDYVJJVmNBcE9aZF95Y1Nxc01LMGpKd0d2YjZVdUl1N3ZBZWdEcG5va0ZUUQ?oc=5" target="_blank">MTVA Stock Se…
MTVA Stock Jumps As Obesity Drug Trial Hits Key Milestone - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTE1lQW8zWmRZcWJRWUZvTzRzWTB2NmN5NVpiMTAwenRub3ZJZkJIRGpkaTVqLS01TC1pbTlLeHExblNZYlZfd3g1RmhVRklfT3ZhSFVxYTIwaVhEVW9wSzJxanRVcTgtNjU1eXp1S2NxVW0?oc=5" target="_blank">MTVA Stock Jumps…
MTVA — Frequently Asked Questions
What is the current share price of MetaVia Inc. (MTVA)?
As of 2026-09-19 21:16 PDT, MetaVia Inc. (MTVA) trades at $1.70 on NasdaqCM. Its 52-week range is $0.97 to $16.50.
What is the market capitalisation of MTVA?
MetaVia Inc. (MTVA) has a market capitalisation of $11.20M on NasdaqCM.
What is the P/E ratio of MTVA?
MTVA trades at a trailing price-to-earnings (P/E) ratio of -0.69. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.67.
Is MTVA a good stock to buy?
This page provides a data-driven analysis of MetaVia Inc. (MTVA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.